Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s stock price fell 8.1% during trading on Tuesday . The company traded as low as $18.83 and last traded at $18.87. 136,419 shares were traded during mid-day trading, a decline of 37% from the average session volume of 214,960 shares. The stock had previously closed at $20.53.
Analyst Ratings Changes
Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a report on Tuesday, August 6th.
Check Out Our Latest Report on Pulse Biosciences
Pulse Biosciences Stock Performance
The company has a market cap of $1.01 billion, a price-to-earnings ratio of -23.84 and a beta of 1.75. The company has a 50-day simple moving average of $15.37 and a 200-day simple moving average of $11.45.
Hedge Funds Weigh In On Pulse Biosciences
A number of large investors have recently made changes to their positions in PLSE. Vanguard Group Inc. increased its position in Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after purchasing an additional 189,227 shares in the last quarter. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the first quarter valued at approximately $109,000. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock valued at $66,000 after buying an additional 2,952 shares during the period. PNC Financial Services Group Inc. acquired a new stake in Pulse Biosciences during the fourth quarter worth approximately $242,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences during the 1st quarter worth $88,000. Hedge funds and other institutional investors own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
